CNS Pharmaceuticals, Inc. — Operating Income by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/7bad746a-d3b3-411b-ae17-c55a6b351514/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-16.0M | 2025-01-01 – 2025-12-31 | evidence 0001683168-26-002550 |
| FY 2024 | $-14.9M | 2024-01-01 – 2024-12-31 | evidence 0001683168-25-002139 |
| FY 2023 | $-18.9M | 2023-01-01 – 2023-12-31 | evidence 0001683168-24-002032 |
| FY 2022 | $-15.3M | 2022-01-01 – 2022-12-31 | evidence 0001683168-23-002086 |
| FY 2021 | $-14.5M | 2021-01-01 – 2021-12-31 | evidence 0001683168-23-002086 |
| FY 2020 | $-9.5M | 2020-01-01 – 2020-12-31 | evidence 0001683168-21-000533 |
| FY 2019 | $-3.8M | 2019-01-01 – 2019-12-31 | evidence 0001683168-20-000781 |
| FY 2018 | $-881.8k | 2018-01-01 – 2018-12-31 | evidence 0001683168-20-000781 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).